Looking ahead, it is possible that anti-OLFML3 therapy, administered concurrently with anti-VEGF therapy, may work synergistically in the GBM microenvironment to mitigate neoangiogenesis and tumor growth. This evidence concerns the gene VEGFA and neoplasm.